Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Voloridge Investment Management LLC

Voloridge Investment Management LLC decreased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 30.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 531,836 shares of the biopharmaceutical company’s stock after selling 235,393 shares during the quarter. Voloridge Investment Management LLC’s holdings in Catalyst Pharmaceuticals were worth $11,099,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of CPRX. Castlekeep Investment Advisors LLC acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $37,494,000. Bank of America Corp DE boosted its stake in shares of Catalyst Pharmaceuticals by 139.5% during the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company’s stock valued at $32,741,000 after buying an additional 913,843 shares during the last quarter. abrdn plc purchased a new position in shares of Catalyst Pharmaceuticals during the 4th quarter valued at approximately $10,115,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Catalyst Pharmaceuticals by 131.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 698,152 shares of the biopharmaceutical company’s stock valued at $14,570,000 after buying an additional 396,506 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company’s stock valued at $175,957,000 after buying an additional 390,116 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 44,904 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at $1,521,404.57. This trade represents a 39.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares in the company, valued at $4,333,200.72. This trade represents a 25.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 351,879 shares of company stock worth $8,214,815 over the last ninety days. 10.40% of the stock is owned by insiders.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX opened at $24.49 on Friday. The business’s fifty day moving average price is $23.53 and its 200 day moving average price is $22.56. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.16. The stock has a market capitalization of $2.99 billion, a PE ratio of 20.75, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Wall Street Zen upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Finally, Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, March 3rd. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $32.29.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.